abbexa 🔿

PEPTIDES FOR CANCER RESEARCH

Abbexa is a supplier of biological tools, providing the scientific community with primary antibodies, secondary antibodies, proteins, ELISA kits and enzymes as well as other kits and tools for use in research.

Working with various laboratories across the World, we aim to develop relevant, high quality, tested products for the biomedical research market.







P53 is a peptide that is best known to induce growth arrest or apoptosis in many tumour types, acting as a tumour suppressor. Defects in P53 have been found to be the cause of numerous cancers. P53 is also involved in cell cycle regulation as transactivator that negatively regulates cell division.





abbexa 🔶

abx063384

Can be used to block the reactivity of the abx008610 p53 Antibody. Sizes: 1mg, 5mg Reactivity: Human, Rat, Monkey Tested Applications: BL Purity: >85%

abx063385

Can be used to block the reactivity of the abx008609 p53 Antibody. Sizes: 1mg, 5mg Reactivity: Human Tested Applications: BL Purity: >85%

abx161505

Can be used to block the reactivity of the abx121795 p53 Antibody. Sizes: 1mg, 5mg Reactivity: Human, Mouse, Rat Tested Applications: BL Gene Symbol: TP53 Gene ID: 7157, 22059, 24842 Purity: >855

abx162067

Can be used to block the reactivity of the

abx133358 p53 Antibody. Sizes: 1mg, 5mg Reactivity: Human Tested Applications: BL Gene Symbol: TP53 Purity: >85%

abx162208

Can be used to block the reactivity of the abx134516 p53 Antibody. Sizes: 1mg, 5mg Reactivity: Human Tested Applications: BL Gene Symbol: TP53 Gene ID: 7157 Purity: >85%

abx162209

Can be used to block the reactivity of the abx134519 p53 Antibody. Sizes: 1mg, 5mg Reactivity: Human, Rat, Monkey Tested Applications: BL Gene Symbol: TP53 Gene ID: T1572442 Purity: >85%

CYFRA 21-1


CYFRA21-1 was more important in metastasis occurrence and in predicting poor prognosis in lung cancer patients than CEA, NSE and positive numbers of biomarkers. Serum CYFRA21-1 was highly elevated in breast cancer patients than in controls and was significantly associated with tumor size, clinical stage and axillary lymph node involvement.



BCL-2



BCL-2 is considered an important target for the treatment of conventional cytotoxic cancer therapies. These therapies rely upon eliciting programmed cell death (apoptosis) in tumour cells. This process is principally regulated by the BCL-2 protein family.



CDK1, Cyclin-dependant Kinase 1, is considered a promising target in the treatment of Colorectal Cancer (CRC). It promotes G2-M transition, regulates G1 progress and G1-S transition, and has been reported to be upregulated in CRC circulating tumour cells.

